Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas Authors retain all rights in any data supplements ...
News-Medical.Net on MSN
New tool can predict cancer recurrence risk in patients with pancreatic neuroendocrine tumors
Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients ...
Dr. Aman Chauhan, leader of the Neuroendocrine Tumor Program at Sylvester Comprehensive Cancer Center, is leading a clinical trial testing a combination of immunotherapy drugs and a tumor-busting ...
Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited ...
Tackling high-grade neuroendocrine tumors, unlocking the mysteries of kidney cancer metabolism, making comprehensive cancer services more accessible, emerging trends after an FDA committee ruling ...
Genitourinary medical oncologist Dr. Michael Morris is part of a new MSK program focused on better treatments for neuroendocrine cancers, which sometimes develop when prostate and lung cancers become ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback